바이오의약품 시장 : 제품 유형별, 치료 용도별, 지역별

Biopharmaceuticals Market, By Product Type, By Therapeutic Application, and By Geography

US $ 4,500 ￦ 6,269,000

Unprintable PDF & Excel (Single User License)

US $ 7,000 ￦ 9,753,000

PDF & Excel (Multi User License - Up to 7 Users)

US $ 10,000 ￦ 13,933,000

PDF & Excel (Corporate User License)

한글목차

바이오의약품 시장은 2025년에 4,582억 1,000만 달러, 2032년에는 7,552억 6,000만 달러에 이를 것으로 예측되며, 2025-2032년 연평균 복합 성장률(CAGR)은 7.4%를 나타낼 전망입니다.

보고서 범위		보고서 상세
기준 연도	2024	2025년 시장 규모	4,582억 1,000만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간(2025-2032년) CAGR	7.40%	2032년 가치 예측	7,552억 6,000만 달러

바이오의약품은 생물 유래의 원료로부터 제조, 추출, 반합성된 치료제를 말합니다. 바이오의약품에는 백신, 치료용 단백질, 혈액 및 혈액 성분, 조직 등 다양한 제품이 포함됩니다. 바이오 의약품은 현대 과학의 가장 정교하고 우아한 성과 중 하나입니다.

시장 역학:

만성질환, 감염성 질환, 신경질환의 부담 증가, 노인 인구 증가, 연구개발(R&D) 증가, 코로나19(팬데믹)의 발생은 세계 바이오의약품 시장의 성장을 증가시킬 것으로 예상되는 주요 요인입니다.

예를 들어, Phanes Therapeutics, Inc.는 2022년 10월 미국 식품의약국(FDA)으로부터 소세포폐암(SCLC) 및 기타 신경내분비암 환자를 대상으로 개발 중인 항 델타 유사 리간드 3(DLL3)/항분화 클러스터 47(CD47) 이중 특이성 항체 PT217의 임상 1상 시험 개시를 허가받았습니다. 미국 식품의약국(FDA)으로부터 임상 1상 시험 개시 허가를 받았으며, PT217은 최근 SCLC 치료제로 FDA로부터 희귀질환 치료제로 지정되었습니다.

본 조사의 주요 특징

• 본 보고서는 세계 바이오의약품 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 2025-2032년의 예측 기간 동안 시장 규모와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 바이오 의약품 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
• 바이오 의약품 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 바이오의약품 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 발매 및 승인
• PEST 분석
• PORTER 분석
• 인수합병(M&A) 시나리오

제4장 세계의 바이오의약품 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 세계의 바이오의약품 시장 : 제품 유형별, 2020년-2032년

• 단일클론항체
• 재조합 성장인자
• 정제 단백질
• 재조합 단백질
• 재조합 호르몬
• 백신
• 재조합 효소
• 세포 및 유전자 치료
• 합성 면역조절제
• 기타 제품 유형

제6장 세계의 바이오의약품 시장 : 치료 용도별, 2020년-2032년

• 종양학
• 염증성 질환 및 감염증
• 자가면역질환
• 대사장애
• 호르몬 장애
• 심혈관질환
• 신경질환
• 기타 질환

제7장 세계의 바이오의약품 시장 : 지역별, 2020-2032년

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• Amgen Inc.
• Abbvie Inc.
• GlaxoSmithKline PLC
• Pfizer Inc.
• Novo Nordisk AS
• Novartis AG
• Johnson & Johnson
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.

제9장 섹션

• 조사 방법
• 출판사에 대해

LSH

영문 목차

영문목차

Biopharmaceuticals Market is estimated to be valued at USD 458.21 Bn in 2025 and is expected to reach USD 755.26 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 458.21 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.40%	2032 Value Projection:	USD 755.26 Bn

A biopharmaceutical is a therapeutic drug manufactured in, extracted from, or semi-synthesized from biological sources. Biopharmaceuticals include a wide range of products such as vaccines, therapeutic proteins, blood and blood components, tissues, etc. Biopharmaceuticals are among the most sophisticated and elegant achievements of modern science.

Market Dynamics:

Increasing burden of chronic, infectious, and neurological diseases, growing geriatric population, increase in research and development (R&D), and outbreak of COVID-19 (pandemic) are major factors expected to augment the growth of the global biopharmaceuticals market.

For instance, in October 2022, Phanes Therapeutics, Inc. received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47) bispecific antibody being developed for patients with small cell lung cancer (SCLC) and other neuroendocrine cancer. PT217 recently been granted an orphan drug designation by the FDA for the treatment of SCLC.

Key features of the study:

• This report provides in-depth analysis of the global biopharmaceuticals market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global biopharmaceuticals market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Amgen Inc., GlaxoSmithKline PLC, Pfizer Inc., Novo Nordisk AS, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Bristol-Myers Squibb Company, Abbvie Inc., and F. Hoffmann-La Roche Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceuticals market.

Detailed Segmentation:

• Global Biopharmaceuticals Market, By Product Type:
  • Monoclonal Antibodies
  • Recombinant Growth Factors
  • Purified Proteins
  • Recombinant Proteins
  • Recombinant Hormones
  • Vaccines
  • Recombinant Enzymes
  • Cell and Gene Therapies
  • Synthetic Immunomodulators
  • Other Product Types
• Global Biopharmaceuticals Market, By Therapeutic Application:
  • Oncology
  • Inflammatory and Infectious Diseases
  • Autoimmune Disorders
  • Metabolic Disorders
  • Hormonal Disorders
  • Cardiovascular Diseases
  • Neurological Diseases
  • Other Diseases
• Global Biopharmaceuticals Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Amgen Inc.
  • Abbvie Inc.
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Novo Nordisk AS
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • F.Hoffmann-La Roche Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Therapeutic Application
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in patient pool and growing geriatric population
  • High-end manufacturing requirements
  • The outbreak of COVID-19 (global pandemic)
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Biopharmaceuticals Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Biopharmaceuticals Market, By Product Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Growth Factors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Purified Proteins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Proteins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Hormones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Enzymes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cell and Gene Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Synthetic Immunomodulators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Other Product Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Biopharmaceuticals Market, By Therapeutic Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Inflammatory and Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Autoimmune Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Metabolic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Hormonal Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cardiovascular Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Neurological Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Other Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Biopharmaceuticals Market, By Geography, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)

8. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novo Nordisk AS
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us

관련자료